Geron Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Geron Corporation - overview
Established
1992
Location
Foster City, CA, US
Primary Industry
Biotechnology
About
Founded in 1992 by Alex Barkas and Michael D West, and based in California, US, Geron Corporation is a biotechnology company that develops and provides telomerase and telomere biology-based cancer-inhibiting drugs such as the Imetelstat in hematologic myeloid malignancies. In March 2024, a consortium comprised of OrbiMed Advisors, Farallon Capital Management, Boxer Capital, Vivo Capital, Deep Track Capital, and RA Capital Management acquired 42 million shares in Geron Corporation at USD 3 apiece, for approximately USD 150 million. Geron is a biopharmaceutical company focused on developing therapies for blood cancers using a novel approach targeting telomerase, an enzyme involved in the uncontrolled proliferation of malignant cells. Their lead product, a telomerase inhibitor, is used for treating adults with low-to-intermediate-1 risk myelodysplastic syndromes who require frequent red blood cell transfusions and have not responded to other treatments.
Current Investors
OrbiMed Advisors, Vivo Capital, RA Capital Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.geron.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Geron Corporation - timeline of key events
Geron Corporation - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 2,438,000 | 2,709,000 | 1,283,000 | 1,153,000 | 36,371,000 | 6,162,000 | 1,065,000 | 1,066,000 | 460,000 | 253,000 | 1,393,000 | 596,000 | - | - | - |
| % Revenue Growth (YoY) | - | 11.1% | (52.6%) | (10.1%) | 3054.5% | (83.1%) | (82.7%) | 0.1% | (56.8%) | (45.0%) | 450.6% | (57.2%) | - | - | - |
| EBITDA (USD) | (93,827,000) | (70,202,000) | (38,180,000) | (36,154,000) | (342,000) | (30,504,000) | (29,147,000) | (31,005,000) | (71,720,000) | (75,799,000) | (111,467,000) | (136,355,000) | - | - | - |
| Operating Income (USD) | (96,116,000) | (71,758,000) | (38,958,000) | (36,312,000) | (559,000) | (30,646,000) | (29,255,000) | (31,073,000) | (72,505,000) | (76,913,000) | (113,999,000) | (138,550,000) | - | - | - |
| Operating Margin | (3942.4%) | (2648.9%) | (3036.5%) | (3149.3%) | (1.5%) | (497.3%) | (2746.9%) | (2914.9%) | (15762.0%) | (30400.4%) | (8183.7%) | (23246.6%) | - | - | - |
| % EBITDA Margin | (3848.5%) | (2591.4%) | (2975.8%) | (3135.6%) | (0.9%) | (495.0%) | (2736.8%) | (2908.5%) | (15591.3%) | (29960.1%) | (8001.9%) | (22878.4%) | - | - | - |
| NET Income (USD) | (96,853,000) | (68,881,000) | (38,379,000) | (35,670,000) | 46,000 | (29,537,000) | (27,916,000) | (27,017,000) | (68,548,000) | (75,617,000) | (116,112,000) | (141,901,000) | - | - | - |
| % Net Margin | (3972.6%) | (2542.7%) | (2991.3%) | (3093.7%) | 0.1% | (479.3%) | (2621.2%) | (2534.4%) | (14901.7%) | (29888.1%) | (8335.4%) | (23808.9%) | - | - | - |
Geron Corporation - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Announced | Geron Corporation | - | ||||||||
| PIPE | Completed | Geron Corporation | - | ||||||||
| Private Debt | Completed | Geron Corporation | - |
Displaying 1 - 3 of 3
Geron Corporation - employee data
Geron Corporation - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member Board Of Directors | BM | ||||||
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.